Innoviva, Inc. (INVA) vs Maze Therapeutics, Inc. (MAZE)
A side-by-side comparison of Innoviva, Inc. and Maze Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
INVA
Innoviva, Inc.
$20.87HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
MAZE
Maze Therapeutics, Inc.
$26.47HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
Total return — INVA vs MAZE
growth of $100 · dividends reinvested · last 2yINVA +9.3% (+4.5%/yr)MAZE +65.7% (+28.7%/yr)MAZE compounded faster over this window
INVA MAZE
INVA vs MAZE: by the numbers
- •INVA is the larger company ($1.54B vs $1.46B market cap).
- •INVA is profitable (80.56% net margin) while MAZE runs a net loss (-667.95%).
Metrics side by side
Valuation
| Metric | INVA | MAZE |
|---|---|---|
| P/E ratio | 5.09 | N/A |
| Forward P/E | 8.62 | N/A |
| PEG ratio | 0.49 | N/A |
| P/S ratio | 3.47 | 73.25 |
| P/B ratio | 1.25 | 3.23 |
| EV / EBITDA | 4.91 | N/A |
| FCF yield | 12.23% | N/A |
Profitability
| Metric | INVA | MAZE |
|---|---|---|
| Gross margin | 73.09% | 0.00% |
| Operating margin | 36.66% | 0.00% |
| Net margin | 80.56% | -667.95% |
| ROE | 28.97% | -29.48% |
| ROIC | 8.36% | -28.63% |
Growth (annualized)
| Metric | INVA | MAZE |
|---|---|---|
| Revenue CAGR (5Y) | 3.94% | N/A |
| EPS CAGR (5Y) | 12.71% | N/A |
| FCF CAGR (5Y) | -10.54% | N/A |
| Total return CAGR (5Y) | 4.52% | N/A |
Frequently asked
- Is INVA or MAZE more profitable?
- INVA runs the higher net margin — INVA at 80.56% versus MAZE at -667.95%.
Go deeper
Dig into the metrics
Innoviva P/E ratioInnoviva ROEMaze Therapeutics ROEInnoviva operating marginMaze Therapeutics operating marginInnoviva revenue growthMaze Therapeutics revenue growthInnoviva free cash flowMaze Therapeutics free cash flow
Innoviva & Maze Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.